Incident HCV-related liver

cancer cases decreased by 47%, and decompensated cirrhosis decreased by 59%, as compared to the base case. Conclusions: While HCV prevalence in Argentina is decreasing, cases of advanced liver disease and liver-related deaths continue to grow. A scenario including large increases in the annual diagnosed and treated populations had a markedly larger impact on future KU-57788 concentration disease burden as compared to a scenario considering only increased SVR. The potential impact of scenarios can inform strategies to increase screening, treatment and control of chronic HCV infection in Argentina. Disclosures: Chris Estes – Consulting: Gilead Homie Razavi – Management Position: Center for Disease Analysis Federico G. Villamil

– Consulting: Novartis, Gador; Grant/Research Support: Janssen Fernando Bessone – Advisory Committees or Review Panels: Schering Plough, Gilead, Glaxo, MSD, Janssen; Speaking and Teaching: Bristol Myers Squibb, Janssen, Bayer, Gilead The following people have nothing to learn more disclose: Ezequiel Ridruejo, Jorge Daruich, Adrian Gadano, Marcelo O. Silva Purpose The CCgenos follow up study is a 5-year prospective, observational cohort study conducted in 25 hospitals across China, investigating treatment patterns and associated clinical outcomes of hepatitis C (HCV) among treatment-naïve Han Chinese patients. Herein Liothyronine Sodium we report the one-year follow-up results of the study. Methods A total of 512 patients out of 996 patients from the CCgenos cross sectional study were enrolled in this follow-up cohort. Patients were enrolled if (1) they provided a signed, informed consent form to participate in the 5-year follow up; and (2) if they did not participate in any investigational drug clinical studies. During the follow-up study, patient visits occur every

3 or 6 months, depending on their treatment status. Blood samples are drawn at all visits and HCV viral load is tested by Abbott RealTime PCR in national central lab. All data are collected via an electronic case report form. Results There were no significant differences between the 512 enrolled patients vs. the 484 excluded patients in age, gender, HCV viral genotypes, IL28B genotypes, CTP scores, HCV RNA viral load, ALT and AST levels, and PLT levels. Among the enrolled 512 patients, 328 (64.1%) patients received HCV treatments at various time points during the first year. Compared to the non-treated group, the treated population is significantly younger (43.3 vs. 52.4 years); there were fewer with HCV viral genotype 1 (57.3% vs. 70.7%), and a lower incidence of cirrhosis (6.1% vs. 14.1%). Among patients receiving HCV treatment, 63.4% (n=208) were treated with pegylated interferon (Peg-IFN) plus ribavirin (RBV); 22.3% (n=73) received interferon plus RBV; and 14.3% (n=47) received other treatment regimens.